A public indemnity pool so universities can sponsor first-in-human cancer trials
Universities often refuse to be the legal sponsor of a first-in-human trial because they cannot afford the insurance and liability. A shared public insurance pool would remove that block.
A government- or funder-backed indemnity and insurance pool that covers no-fault compensation and sponsor liability for academic and non-profit sponsored early-phase oncology trials meeting defined quality standards (independent scientific review, GMP product, approved protocol), priced at cost and open to any accredited institution. Sponsor liability and insurance premiums are a frequently cited reason academic legal offices decline to sponsor first-in-human trials of academic products, especially cell and gene therapies, pushing teams to license early on poor terms or to abandon assets. Several countries operate national no-fault schemes for trial injury; extending them to cover sponsor indemnity for academic early-phase trials is a small, cheap change with a large unblocking effect.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
Pages like this
not linked directly; found by shared links- IdeaRegional translational institutes with academic GMP suites and IND teams
Shares A national non-profit contract research organisation for academic oncology trials, A global first-in-human network for academic cancer trials with single ethics review, Hospital-exemption cell therapies at scale, backed by a shared registry, The valley of death between lab and product.
- Key paperReproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication
Shares A national non-profit contract research organisation for academic oncology trials, The valley of death between lab and product.
- IdeaA short pre-surgery drug window as the default early test of new agents
Shares The valley of death between lab and product, Trial design, endpoints and cost.
- InstitutionEORTC
Shares A national non-profit contract research organisation for academic oncology trials, A global first-in-human network for academic cancer trials with single ethics review.